Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children

Document first published:
Page updated:
Topic:
Publication type:

Rituximab is recommended to be available as a treatment option through routine commissioning for nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children within the criteria set out in this document.

This policy is restricted to certain age groups as the evidence review did not identify evidence to support the efficacy of rituximab in pre-pubescent children for this indication.